Last 626.80 INR
Change Today +9.95 / 1.61%
Volume 1.8M
As of 7:05 AM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

cipla ltd (CIPLA) Snapshot

Open
614.10
Previous Close
616.85
Day High
628.10
Day Low
613.75
52 Week High
09/16/14 - 639.10
52 Week Low
02/24/14 - 366.50
Market Cap
503.3B
Average Volume 10 Days
2.8M
EPS TTM
17.29
Shares Outstanding
802.9M
EX-Date
08/6/14
P/E TM
36.3x
Dividend
2.00
Dividend Yield
0.32%
Current Stock Chart for CIPLA LTD (CIPLA)

Related News

No related news articles were found.

cipla ltd (CIPLA) Related Businessweek News

No Related Businessweek News Found

cipla ltd (CIPLA) Details

Cipla Limited manufactures and sells pharmaceutical and personal care products in India and internationally. The company offers active pharmaceutical ingredients; and formulations in therapeutic areas, such as allergy, analgesic, anti malarial, anti-infectives, cardiology, dermatology and cosmeceuticals, diabetology, gastroenterology, HIV-AIDS, hormones and steroids, iron chelators, musculoskeletal, neuropsychiatry, nutritional and ophthalmic products, oncology, respiratory, urology, and women’s health, as well as steroids and hormones. It also provides veterinary products for various animals, including companion, equine, general care, live stock, and poultry. In addition, the company offers inhaled medication and devices comprising metered dose inhalers with dose indicators, dry powder inhalers, nasal sprays, nebulisers, non-electrostatic spacers, and infant and baby masks. It exports raw materials, intermediates, prescription drugs, OTC drugs, and veterinary products to approximately 170 countries worldwide. Cipla Limited was founded in 1935 and is based in Mumbai, India.

Founded in 1935

cipla ltd (CIPLA) Top Compensated Officers

Managing Director, Global Chief Executive Off...
Total Annual Compensation: 137.5M
Whole-Time Director, Member of Mergers & Acqu...
Total Annual Compensation: 12.0M
Compensation as of Fiscal Year 2014.

cipla ltd (CIPLA) Key Developments

Salix Secures Additional Intellectual Property Relating to Rifaximin from Cipla Limited

Salix Pharmaceuticals Ltd. announced that Cipla Limited has granted Salix exclusive rights under certain patent applications in the "Rifaximin Complexes" patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. Additionally, Salix and Cipla have expanded the scope of their 2009 exclusive license agreement whereby Cipla granted Salix exclusive rights in the United States, Canada and Mexico under certain patent rights covering amorphous rifaximin. By means of this amendment to the 2009 agreement, the rights already licensed to Salix in the United States, Canada and Mexico are expanded to include certain patent rights in the European Union, Japan, Australia, New Zealand and South Korea. Salix is required to make an up-front payment and, upon achievement, additional regulatory milestone payments to Cipla in respect of the new license agreement regarding the "Rifaximin Complexes" patent rights. Salix also will pay royalties on net sales of products covered by the "Rifaximin Complexes" patents licensed to Salix.

Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd and Emcure Pharmaceuticals Ltd Sign Licensing Deals with Gilead Sciences Inc. to Sell a Low-Cost Version of its $1,000-a-Day Hepatitis C Drug Sovaldi

Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd. and Emcure Pharmaceuticals Ltd. are among six generic drug makers that are likely to sign licensing deals with Gilead Sciences Inc. to sell a low-cost version of its $1,000-a-day Hepatitis C drug Sovaldi. The licensing agreements will allow the generic drug companies to make and sell copies of the expensive pill for low- and middle-income countries at lower prices. By signing the licensing agreements with generic drug makers, Gilead is responding to criticism from governments and advocacy groups about the high pricing of the drug that has put it beyond the reach of most patients, particularly those in developing nations. The once-a-day pill used in combination with other antivirals is, however, the most effective therapy to counter Hepatitis C, which kills about 350,000 people a year globally.

Cipla Plans to Launch Salmeterol/Fluticasone Generic Product in the Czech Republic and Slovakia

Cipla has announced that it plans to launch its salmeterol/fluticasone generic product in the Czech Republic and Slovakia under the trade name Fullhale.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CIPLA:IN 626.80 INR +9.95

CIPLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 968.25 INR +20.80
Cadila Healthcare Ltd 1,322 INR -7.75
Dr Reddy's Laboratories Ltd 3,230 INR +21.40
Lupin Ltd 1,396 INR -0.2999
Ranbaxy Laboratories Ltd 639.70 INR +12.85
View Industry Companies
 

Industry Analysis

CIPLA

Industry Average

Valuation CIPLA Industry Range
Price/Earnings 40.4x
Price/Sales 4.6x
Price/Book 4.8x
Price/Cash Flow 30.0x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPLA LTD, please visit www.cipla.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.